Cargando…

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) among young children. A bivalent stabilized prefusion F subunit vaccine (RSVpreF) for pregnant people to protect their infants against RSV-LRTI is currently under review by the US Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanau, Ahuva, Shea, Kimberly M, Weycker, Derek, Atwood, Mark, Quinn, Erin, Kutrieb, Emily, Atwell, Jessica E, Cane, Alejandro D, Gessner, Bradford J, Pugh, Sarah J, Law, Amy W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678367/ http://dx.doi.org/10.1093/ofid/ofad500.096

Ejemplares similares

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults
por: Baber, James A, et al.
Publicado: (2023)

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
por: Chandler, Reynaldo, et al.
Publicado: (2022)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
por: Guiñazú, Javier Ruiz, et al.
Publicado: (2020)

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
por: Tica, Jelena, et al.
Publicado: (2020)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
por: Bartsch, Yannic C., et al.
Publicado: (2023)

1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated
por: Schwarz, Tino, et al.
Publicado: (2020)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

Phase 2b Study of an Ad26.RSV.preF Vaccine for Prevention of RSV-mediated Respiratory Tract Disease in Older Adults
por: Falsey, Ann, et al.
Publicado: (2021)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein
por: Cimica, Velasco, et al.
Publicado: (2016)

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine
por: Walsh, Edward E, et al.
Publicado: (2021)

Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F
por: Harshbarger, Wayne, et al.
Publicado: (2020)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s7aed45piglpq3e1mhmpbfm1c9